Proteasome subunit beta type-5 and Proteasome subunit beta type-8 (PSMB5 and PSMB8)

The Proteasome subunit beta type-5 (PSMB5) and Proteasome subunit beta type-8 (PSMB8, also known as beta-5i or LMP7) are the primary chymotrypsin-like catalytic components of the constitutive proteasome and immunoproteasome, respectively (UniProt P28074, P28062). These subunits are responsible for the degradation of polyubiquitinated proteins, a process essential for maintaining cellular proteostasis, regulating the cell cycle, and modulating signal transduction pathways such as NF-kappaB (PubMed: 29109444). While PSMB5 is ubiquitously expressed, PSMB8 is highly expressed in hematopoietic cells or induced by inflammatory cytokines like interferon-gamma to optimize peptide generation for MHC class I antigen presentation (PubMed: 30604335). In oncology, particularly in multiple myeloma and mantle cell lymphoma, these subunits are critical therapeutic targets because malignant plasma cells are highly dependent on proteasome activity to manage the stress of high protein synthesis (NIH: StatPearls). Drugs like bortezomib and carfilzomib bind to these subunits to inhibit their proteolytic activity, triggering the unfolded protein response and subsequent apoptosis in cancer cells (PubChem). Beyond oncology, selective inhibition of the beta-5i subunit is being explored as a strategy for treating autoimmune and inflammatory disorders by modulating the immune response without the broad toxicity associated with constitutive proteasome inhibition (PubMed: 31558480).

Other names

PSMB5PSMB8LMP7Proteasome subunit beta-5Proteasome subunit beta-8RING10Chymotrypsin-like catalytic subunits20S proteasome beta 5 and beta 5i

Inhibition of the chymotrypsin-like (CT-L) proteolytic activity of the 20S proteasome core, leading to the accumulation of ubiquitinated proteins, inhibition of NF-kappaB signaling, and induction of apoptosis (PubMed: 29109444).